Twist Bioscience Licenses Invenra's B-Body Platform to Expand Bispecific Antibody Discovery Services

MT Newswires Live02-17

Twist Bioscience (TWST) said Tuesday that it has entered a licensing agreement with Invenra to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform.

The companies will jointly offer the B-Body platform, which enables the rapid and precise expression and screening of complex bispecific antibodies, under the agreement, Twist said.

Financial terms include a $5 million upfront cash payment and $15 million in Twist common stock to Invenra, according to the company.

In a separate transaction, Twist will acquire an approximately 6% ownership stake in Invenra through a $13.8 million preferred stock purchase using Twist shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612522384?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612522384","market":"sg","top_or_hot":-1,"title":"Twist Bioscience Licenses Invenra's B-Body Platform to Expand Bispecific Antibody Discovery Services","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TWST\">Twist Bioscience</a> (TWST) said Tuesday that it has entered a licensing agreement with Invenra to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform.</p><p>The companies will jointly offer the B-Body platform, which enables the rapid and precise expression and screening of complex bispecific antibodies, under the agreement, Twist said.</p><p>Financial terms include a $5 million upfront cash payment and $15 million in Twist common stock to Invenra, according to the company.</p><p>In a separate transaction, Twist will acquire an approximately 6% ownership stake in Invenra through a $13.8 million preferred stock purchase using Twist shares.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twist Bioscience Licenses Invenra's B-Body Platform to Expand Bispecific Antibody Discovery Services</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwist Bioscience Licenses Invenra's B-Body Platform to Expand Bispecific Antibody Discovery Services\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-17 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TWST\">Twist Bioscience</a> (TWST) said Tuesday that it has entered a licensing agreement with Invenra to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform.</p><p>The companies will jointly offer the B-Body platform, which enables the rapid and precise expression and screening of complex bispecific antibodies, under the agreement, Twist said.</p><p>Financial terms include a $5 million upfront cash payment and $15 million in Twist common stock to Invenra, according to the company.</p><p>In a separate transaction, Twist will acquire an approximately 6% ownership stake in Invenra through a $13.8 million preferred stock purchase using Twist shares.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612522384","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612522384","pubTimestamp":1771333733,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Twist Bioscience  said Tuesday that it has entered a licensing agreement with Invenra to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform.The companies will jointly offer the B-Body platform, which enables the rapid and precise expression and screening of complex bispecific antibodies, under the agreement, Twist said.Financial terms include a $5 million upfront cash payment and $15 million in Twist common stock to Invenra, according to the company.In a separate transaction, Twist will acquire an approximately 6% ownership stake in Invenra through a $13.8 million preferred stock purchase using Twist shares.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","TWST":"Twist Bioscience Corp"},"translate_title":"Twist Bioscience授权Invenra的B-Body平台扩展双特异性抗体发现服务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Twist Bioscience (TWST) said Tuesday that it has entered a licensing agreement with Invenra to become a co-exclusive provider of Invenra's B-Body bispecific antibody platform.The companies will jointly offer the B-Body platform, which enables the rapid and precise expression and screening of complex bispecific antibodies, under the agreement, Twist said.Financial terms include a $5 million upfront cash payment and $15 million in Twist common stock to Invenra, according to the company.In a separate transaction, Twist will acquire an approximately 6% ownership stake in Invenra through a $13.8 million preferred stock purchase using Twist shares.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612522384","isCrawlerRequest":true}